FSD Pharma Receives Full “Sale for Medical Purposes” Cannabis License from Health Canada

-Full license allows FSD to deliver cannabis to medicinal use markets
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”) has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license is effective as of June 21, 2019. read more

World Class and Quadron Announce Closing of Plan of Arrangement

World Class Extractions Inc. (“World Class”) (CSE: PUMP) and Quadron Cannatech Corporation (“Quadron”) (CSE: QCC) are pleased to announce that that they have completed their previously announced plan of arrangement (the “Arrangement”) under the provisions of the Business Corporations Act (British Columbia), pursuant to which World Class has acquired all of the common shares of Quadron (the “Quadron Shares”) following Quadron’s amalgamation with World Class’s wholly-owned subsidiary, 1212476 B.C. LTD., to form a new wholly-owned subsidiary of World Class continuing as “Quadron Cannatech Corporation” (“Amalco”). read more

FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company’s Board of Directors. read more

FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board

Ziva Cooper, Ph.D. and Mallory Loflin, Ph.D. become latest members of the renowned group of FSD Scientific Advisors led by Charles Pollack, Jr. MD, FACEP
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), is pleased to announce the addition of two distinguished cannabis researchers to the company’s Scientific Advisory Board (“SAB”). read more

Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention

Panel to Feature Discussion About Creating a Winning Culture in the Biotech Industry
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that Executive Co-Chairman and Chief Executive Officer, Dr. Raza Bokhari, will be featured in the 2019 BIO International Convention’s panel presentation, “Building a Winning Team for Biotech Business Success – Lessons You Can Learn from Industry Veterans and Former NFL Player Turned Broadcaster Solomon Wilcots,” on June 4 in Philadelphia, PA. read more

FSD Pharma Names Raza Bokhari, M.D. as Permanent CEO

Company Also Reports Q1 2019 Financial Results
C.HUGE, FSD Pharma, cannabis, pot

The Board of Directors of FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), unanimously voted Raza Bokhari, M.D., Executive Co-Chairman of the Board, as permanent Chief Executive Officer. Dr. Bokhari has served as interim CEO of the Company since February. read more

FSD Pharma Congratulates High Tide on the Resumption of Retail Cannabis Licensing by AGLC in Alberta

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) would like to congratulate High Tide Inc. (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) (“High Tide”) on the recent announcement from Alberta Gaming, Liquor and Cannabis lifting the moratorium on issuing cannabis licenses and accepting license applications. The announcement is an encouraging sign of steadily improving cannabis supply levels in Alberta and is a positive step for companies like High Tide that have numerous stores ready and waiting to retail cannabis products. read more

Edward Brennan, Jr., M.D., FACS to Lead FSD Pharma BioSciences Division

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), today announced the appointment of pharmaceutical industry leader, Edward J. Brennan, Jr., M.D., FACS, as President of its biosciences division. Dr. Brennan has more than 25 years’ experience in leadership roles at major pharmaceutical companies and clinical research organizations. read more

World Class Extractions Acquisition Target, Quadron Cannatech Introduces the “BIG BEAST” – the Latest Member of the BEAST Family of Extraction Systems to Process Over 5,000,000 kg of Cannabis or Hemp Per Year

World Class Extractions Inc. (“World Class”) (CSE: PUMP) (FRA:WCF) is pleased to announce that its acquisition target Quadron Cannatech Corporation (the “Company” or “Quadron”) (CSE: QCC), will begin to take reservations to toll process hemp or cannabis with the “BIG BEAST”, a fully automated, touch screen control continuous flow Ethanol Extractor System. The “BIG BEAST is the latest addition to the BEAST family of extractors, with estimated processing capacity of up to 20,000 kg of biomass per day – over 5,000,000 kg of biomass annually. read more

FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board

Daniele Piomelli, Ph.D., Ryan Vandrey, Ph.D. and David Casarett, MD, MA Join distinguished group of Scientific Advisors
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), is pleased to announce that three eminent cannabis researchers have joined the company’s Scientific Advisory Board (“SAB”). read more